Ikonisys and Ulisse Biomed Announce Strategic Partnership to Support Innovation in Cancer Diagnostics
June 11 2024 - 11:30AM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a
company specializing in the early and accurate detection of cancers
through a unique, fully automated solution for medical analysis
laboratories, and Ulisse Biomed S.p.A. (“UBM”) are pleased
to announce a strategic collaboration to enhance their technical
and commercial capabilities in cancer diagnostics.
UBM is a healthcare biotech company operating in diagnostics,
theranostics and therapeutics, and thus capable of generating
innovative and competitive products in these fields thanks to its
three proprietary technology platforms.
A key aspect of this collaboration is the integration of UBM’s
expertise in Molecular Biology alongside with Ikonisys’
Liquid-Based Cytology (LBC) and Fluorescence In Situ Hybridization
(FISH) technology. This integration is set to provide innovative
cancer diagnostics by offering comprehensive and precise diagnostic
capabilities that can greatly enhance patient outcomes. In the
framework of this partnership:
- The Companies will explore cross-selling and co-marketing
opportunities through their sales networks to maximize market
penetration and leverage product and service synergies. A mutual
distribution agreement will be defined in a second step.
- Ikonisys and UBM are committed to working together to explore
and develop new business opportunities. This partnership reflects
their shared goal of innovating and growing by combining skills and
resources. A technical deep dive will also thus be conducted to
discuss potential production and OEM agreements, aiming to optimize
production techniques and ensure high product quality. This
initiative will integrate the technical expertise of both
Companies, promoting innovative and competitive solutions in cancer
diagnostics.
The partnership will first take place with the installation and
mutual training of instruments at Hospitex Lab in Florence, part of
the IKONISYS Group1, which is scheduled between end of June and
mid-July. Thanks to this cooperation, the Companies will be able to
familiarize themselves with each other's technologies and
expertise, fostering closer technical cooperation.
In Autumn 2024, Ikonisys and UBM will co-organize a demo day to
showcase their technologies and products to customers. This event
will be the opportunity to assess the added value of their
collaboration, allowing direct interaction with customers,
gathering feedback, and thus identifying market opportunities.
Nicola Basile, CEO of Ulisse Biomed, stated: “We consider
Ikonisys as a partner with many strategical fits with UBM Group,
from a technological perspective to a commercial synergy. We
foresee a great collaboration ahead. In the last months, we have
been working on our integration with Hyris and this partnership
confirms we are on the right path to be a relevant player in the
market with significant solutions for customers and prospects.”
Mario Crovetto, CEO of Ikonisys, added: “UBM’s innovative
technology and vision are perfectly aligned to Ikonisys’
development strategy, especially with the recent integration of
Hyris. Following the announcement of Hospitex integration on our
end, which is still ongoing, this partnership attests of our
relentless commitment to further maximizing value for our
shareholders and offering integrated and accurate diagnostics
solutions to our customers. By joining forces with UBM, we are
positioned to accelerate our growth strategy, by further broadening
our core business and expanding our sales network.”
About Ulisse BioMed Ulisse Biomed S.p.A. is the head of a
healthcare biotech group active in the development of innovative
solutions in the fields of diagnostics, theranostics and
therapeutics. Through its subsidiary Hyris Limited, the group
operates in the cloud computing sector in the biotech field. UBM
and Hyris constitute an integrated group operating in the in vitro
diagnostics industry, and in particular in molecular biology, with
a distinctive positioning guaranteed by the presence of the entire
industrial chain and the technological innovation characteristics
of the reagents designed and produced by UBM, on the one hand, and
the instrumentation and interpretation software of Hyris, on the
other.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to https://ikonisys.com/
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
______________________________ 1 “Ikonisys to Acquire Hospitex
International and Become an Integrated Cancer Diagnostic Leader”,
on November 30, 2023
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240611079237/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Jul 2023 to Jul 2024